Genmab Announces Changes to its Executive Committee
Media Release
COPENHAGEN, Denmark; August 16, 2024
- Rayne Waller joins as Executive Vice President and
Chief Technology Officer
- Brad Bailey appointed as Executive Vice President and
Chief Commercial Officer
- Anthony Mancini, Executive Vice President and Chief
Operating Officer, will leave Genmab to pursue other
opportunities
Genmab A/S (Nasdaq:
GMAB) today
announced changes to its Executive Committee to support
Genmab’s growth and evolution into a fully integrated biotech
innovation powerhouse. Genmab’s Executive Committee will
include Rayne Waller in the newly created role of Executive Vice
President and Chief Technology Officer and Brad Bailey in the newly
created role of Executive Vice President and Chief Commercial
Officer. Executive Vice President and Chief Operating Officer
Anthony Mancini has decided to leave Genmab to pursue other
opportunities.
Rayne and Brad will report directly to Genmab’s President and
CEO Dr. Jan van de Winkel and be based in Copenhagen, Denmark and
Princeton, New Jersey, respectively. They will join Jan and the
rest of the Executive Committee, including Chief Financial Officer
Anthony Pagano, Chief Legal Officer Birgitte Stephensen, Chief
Development Officer Dr. Judith Klimovsky, Chief Medical Officer Dr.
Tahi Ahmadi, Chief People Officer Chris Cozic, and Chief Strategy
Officer Dr. Martine van Vugt.
“I am deeply grateful to Anthony Mancini for his many
contributions to Genmab during his tenure, and on behalf of the
Board of Directors and the Executive Committee, I wish him
continued success in his future endeavors,” said Jan van de Winkel,
Ph.D., Chief Executive Officer of Genmab. “I’m also very pleased to
welcome Rayne Waller and Brad Bailey to the Executive Committee as
exceptionally talented leaders with expertise in their fields.
These new additions strengthen our commitment to envision a bold
future for our diverse and innovative mid- to late-stage clinical
programs and pipeline that can impact the lives of as many patients
as possible. I am confident in their ability to energize our teams
and execute towards our 2030 vision to transform the lives of
people with cancer and other serious diseases with
knock-your-socks-off (KYSO®) antibody medicines.”
Rayne will further solidify and strengthen Genmab’s technical
operations capabilities and lead all the manufacturing and supply
chain capabilities of Genmab’s proprietary programs through
preclinical, clinical and commercial stages. Brad, who served
Genmab as Senior Vice President and US General Manager, has been
promoted to lead the direction, planning, and execution of Genmab’s
global commercial strategies. He will continue as US General
Manager on an interim basis.
Rayne brings more than 30 years of international
biopharmaceutical experience, including CMC (chemistry,
manufacturing and controls) operations, supply chain management,
corporate governance, and oversight of multi-product, multi-ton
production and multi-billion-dollar inventory management. Rayne was
most recently Chief Operating Officer at Capsida Biotherapeutics,
and he spent 27 years at Amgen, where he progressed through
hands-on and strategic positions of increasing scope and
responsibilities in product production, packaging, distribution,
logistics, and plant and supply chain management.
Brad joined Genmab in 2020 as the company’s first General
Manager in the United States. As part of this role, he led the
company’s US commercialization organization, including driving the
successful launches and co-commercialization partnerships for
tisotumab vedotin and epcoritamab. Brad brings more than 25 years
of experience in the healthcare industry, with focus in oncology,
immunology, and other serious diseases. He has extensive experience
in strategic and operational leadership roles in the US and
globally, including at Ipsen, UCB, and Pfizer.
About Genmab
Genmab is an international biotechnology company with a core
purpose of guiding its unstoppable team to strive toward improving
the lives of patients with innovative and differentiated antibody
therapeutics. For 25 years, its passionate, innovative and
collaborative team has invented next-generation antibody technology
platforms and leveraged translational, quantitative and data
sciences, resulting in a proprietary pipeline including bispecific
T-cell engagers, antibody-drug conjugates, next-generation immune
checkpoint modulators and effector function-enhanced antibodies. By
2030, Genmab’s vision is to transform the lives of people with
cancer and other serious diseases with knock-your-socks-off
(KYSO®) antibody medicines.
Established in 1999, Genmab is headquartered in Copenhagen,
Denmark, with international presence across North America, Europe
and Asia Pacific. For more information, please visit Genmab.com and
follow us on LinkedIn and X.
Contact:
Marisol Peron, Senior Vice President, Global Communications &
Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
This Media Release contains forward looking statements. The
words “believe,” “expect,” “anticipate,” “intend” and “plan” and
similar expressions identify forward looking statements. Actual
results or performance may differ materially from any future
results or performance expressed or implied by such statements. The
important factors that could cause our actual results or
performance to differ materially include, among others, risks
associated with preclinical and clinical development of products,
uncertainties related to the outcome and conduct of clinical trials
including unforeseen safety issues, uncertainties related to
product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive
environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and
proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our
products or technologies obsolete, and other factors. For a further
discussion of these risks, please refer to the risk management
sections in Genmab’s most recent financial reports, which are
available on www.genmab.com and the risk factors
included in Genmab’s most recent Annual Report on Form 20-F and
other filings with the U.S. Securities and Exchange
Commission (SEC), which are available at
www.sec.gov. Genmab does not undertake any obligation
to update or revise forward looking statements in this Media
Release nor to confirm such statements to reflect subsequent events
or circumstances after the date made or in relation to actual
results, unless required by law.
Genmab A/S and/or its subsidiaries own the following
trademarks: Genmab®; the Y-shaped
Genmab logo®; Genmab in combination
with the Y-shaped Genmab logo®;
HuMax®;
DuoBody®;
HexaBody®;
DuoHexaBody®,
HexElect® and
KYSO®.
Media Release no. i12
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122
Genmab A/S
Carl Jacobsens Vej 30
2500 Valby
Denmark
- 08162024_MRi12_Genmab Executive Committee Changes
Genmab AS (TG:GE9)
Historical Stock Chart
From Oct 2024 to Nov 2024
Genmab AS (TG:GE9)
Historical Stock Chart
From Nov 2023 to Nov 2024
